PTX Media related, page-1069

Well, consultation with the charts doesn't seem to suggest that the status of PTX200 was the reason for the drop to 8.5c. PTX has pretty much been in synch with the XJO downward move since early Feb. There was a long-wicked doji on Feb 7, though, akin to an entity probing the lower levels which was quickly bought up. It was only in the following week that the SP took a definitive drop into single digits... again in synch with the falls across the ASX. And, as been discussed a lot, options expiry has factored in heavily on the SP. Besides, PTX200 hasn't been dropped as such... it is ongoing with a data readout due at the EOFY. Upon completion of the trial (which after listening to the webcast again, I realise is still a while off), a decision will need to be made as to whether the cost of pursuing a next phase combination trial is in our best interests of the company to finance or whether a "farm out" has more merit. Like I think most would agree, our OmniCAR trial in AML should be our priority and if another biotech wants to incorporate PTX200 as a targeted therapy into their trial... great... if not, at least we don't have to spend money competiting in what is now a more crowded space, I don't think SH or prospective SH were phased by that reality being conveyed by SYC in the webcast. We only need one of our targeted therapies to be a game-changer for the company and that now appears to be PTX100.